Business
BBOT to Participate in Upcoming December Investor Healthcare Conferences
SOUTH SAN FRANCISCO, Calif., Nov. 18, 2025 (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc. (“BBOT”) (Nasdaq: BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway malignancies, today announced that members of its leadership team will participate in two investor conferences in December. Details of the company’s participation are as follows: Piper Sandler 37th Annual Healthcare ConferencePresentation: Tuesday, December 2, at 2:00 p.m. ET 8th Annual Evercore Healthcare
About this update from Bridgebio Oncology Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Nov. 18, 2025 (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc. (“BBOT”) (Nasdaq: BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway malignancies, today announced that members of its leadership team will participate in two investor conferences in December. Details of the company’s participation are as follows: Live webcasts of the presentations will be accessible on the “ Events ” page of the BBOT website at https://investors.bbotx.com/news-events/events . Replays of the webcasts will be available for at least 90 days following the event. About BBOT BBOT is a clinical-stage biopharmaceutical company advancing a next-generation pipeline of novel small molecule therapeutics targeting RAS and PI3Kα malignancies. BBOT has the goal of improving outcomes for patients with cancers driven by the two most prevalent oncogenes in human tumors. For more information, please visit www.bbotx.com and follow us on LinkedIn . BBOT Contacts: Investor Contact: Heather Armstrong BBOT [email protected] Media Contact: Jake Robison Inizio Evoke Comms [email protected]
View stock analysis, news, and events for Bridgebio Oncology Therapeutics, Inc.